Novo Nordisk shares dive after heart medicine fails trial
The experimental medicine ziltivekimab didn’t translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
Novo Nordisk shares dive after heart medicine fails trial
The experimental medicine ziltivekimab didn’t translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
Novo Nordisk shares dive after heart medicine fails trial
The experimental medicine ziltivekimab didn’t translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline
The experimental medicine ziltivekimab didn’t translate into a statistically meaningful reduction in major cardiovascular adverse events, Novo said Friday.
The Tech Download: Anduril CEO Brian Schimpf talks AI in warfare and manufacturing push
CNBC’s Arjun Kharpal sits down on The Tech Download podcast with the defense company chief.
The Tech Download: Anduril CEO Brian Schimpf talks AI in warfare and manufacturing push
CNBC’s Arjun Kharpal sits down on The Tech Download podcast with the defense company chief.
The Tech Download: Anduril CEO Brian Schimpf talks AI in warfare and manufacturing push
CNBC’s Arjun Kharpal sits down on The Tech Download podcast with the defense company chief.
The Tech Download: Anduril CEO Brian Schimpf talks AI in warfare and manufacturing push
CNBC’s Arjun Kharpal sits down on The Tech Download podcast with the defense company chief.
Hamas says Trump’s Gaza ‘disarmament’ claim depends on Israel honoring commitments
Hamas says it will only disarm after Israel meets previous ceasefire commitments, despite President Trump’s announcement of a breakthrough U.S.-brokered agreement.
A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors
Janus Henderson’s Julian McManus says investors are looking overseas as Magnificent Seven concentration worries revive diversification.




